These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Cervical adenocarcinoma in users of oral contraceptives (clinical case)].
    Author: Roa E, Toledo P, Iglesias J.
    Journal: Rev Chil Obstet Ginecol; 1980; 45(4):225-8. PubMed ID: 7323362.
    Abstract:
    The article reports on the case of a 34 year old woman, user of oral contraceptives (OCs) for 13 consecutive years. The patient underwent uterine curettage for metrorrhagia; the histopathologic study of the curetted material showed the presence of a cervical adenocarcinoma. A biopsy done 20 days after curettage confirmed the presence of an endocervical adenocarcinoma. This case is interesting because of the young age of the patient, whereas average age at appearance of adenocarcinoma is 48. A review of the published literature reveals an increase in the number of reported cervical adenocarcinomas, or 8.5% to 10.7% of all types of cervical cancer. The principal symptom of cervical adenocarcinoma is bleeding, in 90% of cases; other symptoms may be abundant cervical mucus and pelvic pain. The relation between cervical adenocarcinoma and individual factors such as age and parity is not clear. A direct relationship between OC treatment and cervical carcinoma, especially prolonged OC use, has often been suggested but never proven. Treatment for cervical cancer consists of pelvic and intracavitary irradiation followed by hysterectomy in stage 1 and 2 of the disease, and irradiation only in stage 3 and 4 of the disease. Survival rate varies from 100% at stage 1 to 28.8% at stage 3.
    [Abstract] [Full Text] [Related] [New Search]